We are live on ! Find out more
ARTL icon

Artelo Biosciences

7 hedge funds and large institutions have $121K invested in Artelo Biosciences in 2025 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

17% more funds holding

Funds holding: 67 (+1)

3.24% more ownership

Funds ownership: 1.64%4.88% (+3.2%)

20% less capital invested

Capital invested by funds: $152K → $121K (-$31.1K)

Holders
7
Holders Change
+1
Holders Change %
+16.67%
% of All Funds
0.08%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
1
Reduced
Closed
4
Calls
Puts
Net Calls
Net Calls Change

ARTL Hedge Fund Activity: Q4 2025 in Review

7 of the 8,280 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q4 2025, worth a combined $121K — down 20% from $152K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new ARTL positions and 4 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.

The largest buyer was UBS Group, adding an estimated $86.4K. The largest seller was DRW Securities, exiting entirely with an estimated $78.9K sold.

  • 7 institutional investors held Artelo Biosciences (ARTL) as of Q4 2025, up from 6 in Q3 2025.
  • Funds reported $121K of Artelo Biosciences stock for Q4 2025, down 20% quarter-over-quarter.
  • 5 funds opened new Artelo Biosciences positions in Q4 2025 and 4 closed out, a net change of +1 holder.
  • The largest Artelo Biosciences buyer in Q4 2025 was UBS Group, an estimated $86.4K added.
  • The largest Artelo Biosciences seller in Q4 2025 was DRW Securities, an estimated $78.9K sold.

Based on aggregated 13F filings for Q4 2025.